|
2025 Journal Article PROGNOSTIC IMPLICATIONS OF PLATELET FCγRIIA DURING THE FIRST YEAR AFTER MYOCARDIAL INFARCTIONSchneider, David J., McMahon, Sean Robert, Angiolillo, Dominick J., Fanaroff, Alexander C., Wanamaker, Brett, Ibrahim, Homam, Effron, Mark B., Hohl, Patrick Kennedy, Shapiro, Timothy Alan, Ball, Kevin M. and DiBattiste, Peter M. (2025). PROGNOSTIC IMPLICATIONS OF PLATELET FCγRIIA DURING THE FIRST YEAR AFTER MYOCARDIAL INFARCTION. Journal of the American College of Cardiology, 85 (12), 1785. doi: 10.1016/s0735-1097(25)02269-7 |
|
2024 Journal Article Platelet fcγriia as a marker of cardiovascular risk after myocardial infarctionSchneider, David J., McMahon, Sean R., Angiolillo, Dominick J., Fanaroff, Alexander, Ibrahim, Homam, Hohl, Patrick K., Wanamaker, Brett L., Effron, Mark B. and DiBattiste, Peter M. (2024). Platelet fcγriia as a marker of cardiovascular risk after myocardial infarction. Journal of the American College of Cardiology, 84 (18), 1721-1729. doi: 10.1016/j.jacc.2024.08.051 |
|
2024 Journal Article Contribution of clinical trial event data by data source a prespecified analysis of the ADAPTABLE randomized clinical trialRymer, Jennifer A., Mulder, Hillary, Wruck, Lisa M., Munoz, Daniel, Kripalani, Sunil, Effron, Mark B., Gupta, Kamal, Handberg, Eileen, Jain, Sandeep, Girotra, Saket, Whittle, Jeffrey, Hess, Rachel, Benziger, Catherine P., Knowlton, Kirk U., Curtis, Lesley H., Roe, Matthew T., Hammill, Bradley G., Rothman, Russell L., Harrington, Robert, Hernandez, Adrian and Jones, W. Schuyler (2024). Contribution of clinical trial event data by data source a prespecified analysis of the ADAPTABLE randomized clinical trial. JAMA Cardiology, 9 (9), E1-E6. doi: 10.1001/jamacardio.2024.2019 |
|
2024 Journal Article Aspirin dosing for secondary prevention of atherosclerotic cardiovascular disease in male and female patients: A secondary analysis of the ADAPTABLE randomized clinical trialBenziger, Catherine P., Stebbins, Amanda, Wruck, Lisa M., Effron, Mark B., Marquis-Gravel, Guillaume, Farrehi, Peter M., Girotra, Saket, Gupta, Kamal, Kripalani, Sunil, Munoz, Daniel, Polonsky, Tamar S., Sharlow, Amber, Whittle, Jeffrey, Harrington, Robert A., Rothman, Russell L., Hernandez, Adrian F. and Jones, W. Schuyler (2024). Aspirin dosing for secondary prevention of atherosclerotic cardiovascular disease in male and female patients: A secondary analysis of the ADAPTABLE randomized clinical trial. JAMA Cardiology, 9 (9) e006292, 808-816. doi: 10.1001/jamacardio.2024.1712 |
|
2024 Journal Article Impact of aspirin dose according to race in secondary prevention of atherosclerotic cardiovascular disease: a secondary analysis of the ADAPTABLE randomised controlled trialMarquis-Gravel, Guillaume, Mulder, Hillary, Wruck, Lisa M, Benziger, Catherine P, Effron, Mark B, Farrehi, Peter M, Girotra, Saket, Gupta, Kamal, Kripalani, Sunil, Muñoz, Daniel, Polonsky, Tamar S, Whittle, Jeff, Harrington, Robert, Rothman, Russell, Hernandez, Adrian F and Jones, WS (2024). Impact of aspirin dose according to race in secondary prevention of atherosclerotic cardiovascular disease: a secondary analysis of the ADAPTABLE randomised controlled trial. BMJ Open, 14 (8) e078197, e078197-8. doi: 10.1136/bmjopen-2023-078197 |
|
2024 Journal Article Age and aspirin dosing in secondary prevention of atherosclerotic cardiovascular diseaseMarquis‐Gravel, Guillaume, Stebbins, Amanda, Wruck, Lisa M., Roe, Matthew T., Effron, Mark B., Hammill, Bradley G., Whittle, Jeff, VanWormer, Jeffrey J., Robertson, Holly R., Alikhaani, Jacqueline D., Kripalani, Sunil, Farrehi, Peter M., Girotra, Saket, Benziger, Catherine P., Polonsky, Tamar S., Merritt, J. Greg, Gupta, Kamal, McCormick, Thomas E., Knowlton, Kirk U., Jain, Sandeep K., Kochar, Ajar, Rothman, Russell L., Harrington, Robert A., Hernandez, Adrian F. and Jones, W. Schuyler (2024). Age and aspirin dosing in secondary prevention of atherosclerotic cardiovascular disease. Journal of the American Heart Association, 13 (4) e026921, 1-9. doi: 10.1161/jaha.122.026921 |
|
2024 Journal Article Characteristics and predictors of apparent treatment-resistant hypertension in real-world populations using electronic health record-based dataJafari, Eissa, Cooper-DeHoff, Rhonda M., Effron, Mark B., Hogan, William R. and McDonough, Caitrin W. (2024). Characteristics and predictors of apparent treatment-resistant hypertension in real-world populations using electronic health record-based data. American Journal of Hypertension, 37 (1), 60-68. doi: 10.1093/ajh/hpad084 |
|
2024 Journal Article Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease and Diabetes Mellitus: A Subgroup Analysis of the ADAPTABLE TrialNarcisse, Dennis I., Kim, Hwasoon, Wruck, Lisa M., Stebbins, Amanda L., Muñoz, Daniel, Kripalani, Sunil, Effron, Mark B., Gupta, Kamal, Anderson, R. David, Jain, Sandeep K., Girotra, Saket, Whittle, Jeff, Benziger, Catherine P., Farrehi, Peter, Zhou, Li, Polonsky, Tamar S., Ahmad, Faraz S., Roe, Matthew T., Rothman, Russell L., Harrington, Robert A., Hernandez, Adrian F. and Jones, W. Schuyler (2024). Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease and Diabetes Mellitus: A Subgroup Analysis of the ADAPTABLE Trial. Diabetes Care, 47 (1), 81-88. doi: 10.2337/dc23-0749 |
|
2023 Journal Article More Potent Antiplatelet Therapy in Acute Coronary Syndrome Patients With Prior Stroke: Proceed With Caution?McKinnie, Christopher M. and Effron, Mark B. (2023). More Potent Antiplatelet Therapy in Acute Coronary Syndrome Patients With Prior Stroke: Proceed With Caution?. Mayo Clinic Proceedings, 98 (11), 1590-1592. doi: 10.1016/j.mayocp.2023.09.014 |
|
2023 Journal Article Aspirin dosing for secondary prevention of atherosclerotic cardiovascular disease in patients treated with P2Y12 inhibitorsGirotra, Saket, Stebbins, Amanda, Wruck, Lisa, Marquis‐Gravel, Guillaume, Gupta, Kamal, Farrehi, Peter, Benziger, Catherine P., Effron, Mark B., Whittle, Jeffrey, Muñoz, Daniel, Kripalani, Sunil, Anderson, R. David, Jain, Sandeep K., Polonsky, Tamar S., Ahmad, Faraz S., Roe, Matthew T., Rothman, Russell L., Harrington, Robert A., Hernandez, Adrian F. and Jones, W. Schuyler (2023). Aspirin dosing for secondary prevention of atherosclerotic cardiovascular disease in patients treated with P2Y12 inhibitors. Journal of the American Heart Association, 12 (20) e030385, 1-10. doi: 10.1161/jaha.123.030385 |
|
2023 Journal Article Effectiveness and safety of enteric-coated vs uncoated aspirin in patients with cardiovascular disease: a secondary analysis of the ADAPTABLE randomized clinical trialSleem, Amber, Effron, Mark B., Stebbins, Amanda, Wruck, Lisa M., Marquis-Gravel, Guillaume, Muñoz, Daniel, Re, Richard N., Gupta, Kamal, Pepine, Carl J., Jain, Sandeep K., Girotra, Saket, Whittle, Jeffrey, Benziger, Catherine P., Farrehi, Peter M., Knowlton, Kirk U., Polonsky, Tamar S., Roe, Matthew T., Rothman, Russell L., Harrington, Robert A., Jones, W. Schuyler and Hernandez, Adrian F. (2023). Effectiveness and safety of enteric-coated vs uncoated aspirin in patients with cardiovascular disease: a secondary analysis of the ADAPTABLE randomized clinical trial. JAMA Cardiology, 8 (11), 1061-1069. doi: 10.1001/jamacardio.2023.3364 |
|
2023 Journal Article Comparison of the effectiveness and safety of 2 aspirin doses in secondary prevention of cardiovascular outcomes in patients with chronic kidney disease: A subgroup analysis of ADAPTABLEGupta, Kamal, Mehta, Harsh, Kim, Hwasoon, Stebbins, Amanda, Wruck, Lisa M., Muñoz, Daniel, Effron, Mark B., Anderson, R. David, Pepine, Carl J., Jain, Sandeep K., Girotra, Saket, DeWalt, Darren A., Whittle, Jeff, Benziger, Catherine P., Farrehi, Peter, Zhou, Li, Knowlton, Kirk U., Polonsky, Tamar S., Bradley, Steven M., Harrington, Robert A., Rothman, Russell L., Jones, W. Schuyler and Hernandez, Adrian F. (2023). Comparison of the effectiveness and safety of 2 aspirin doses in secondary prevention of cardiovascular outcomes in patients with chronic kidney disease: A subgroup analysis of ADAPTABLE. American Heart Journal, 264, 31-39. doi: 10.1016/j.ahj.2023.06.001 |
|
2023 Journal Article Thrombotic risk in patients with acute coronary syndromes discharged on prasugrel or clopidogrel: results from the PROMETHEUS studyChiarito, Mauro, Cao, Davide, Sartori, Samantha, Zhang, Zhongjie, Vogel, Birgit, Spirito, Alessandro, Smith, Kenneth F., Weintraub, William, Strauss, Craig, Toma, Catalin, DeFranco, Anthony, Effron, Mark B., Stefanini, Giulio, Keller, Stuart, Kapadia, Samir, Rao, Sunil V., Henry, Timothy D., Pocock, Stuart, Sharma, Samin, Dangas, George, Kini, Annapoorna, Baber, Usman and Mehran, Roxana (2023). Thrombotic risk in patients with acute coronary syndromes discharged on prasugrel or clopidogrel: results from the PROMETHEUS study. European Heart Journal: Acute Cardiovascular Care, 12 (9), 594-603. doi: 10.1093/ehjacc/zuad083 |
|
2023 Journal Article Novel tissue factor inhibition for thromboprophylaxis in COVID-19: primary results of the ASPEN-COVID-19 TrialHess, Connie N., Hsia, Judith, Carroll, Ian A., Nehler, Mark R., Ruf, Wolfram, Morrow, David A., Nicolau, Jose C., Berwanger, Otavio, Szarek, Michael, Capell, Warren H., Johri, Shilpa, Pursley, Michael S., Gupta, Ryan, Meehan, Patrick S., Franchi, Francesco, Effron, Mark B., Marshall, Debra, Graybill, Christopher A., Graybill, Sophie P., Keuer, Thomas, Bristow, Michael R. and Bonaca, Marc P. (2023). Novel tissue factor inhibition for thromboprophylaxis in COVID-19: primary results of the ASPEN-COVID-19 Trial. Arteriosclerosis, Thrombosis, and Vascular Biology, 43 (8), 1572-1582. doi: 10.1161/atvbaha.122.318748 |
|
2023 Journal Article Internet versus noninternet participation in a decentralized clinical trial: lessons from the ADAPTABLE studyShen, Rebecca, Mulder, Hillary, Wruck, Lisa, Weissler, E. Hope, Robertson, Holly R., Sharlow, Amber G., Kripalani, Sunil, Muñoz, Daniel, Effron, Mark B., Gupta, Kamal, Girotra, Saket, Whittle, Jeff, Benziger, Catherine P., VanWormer, Jeffrey J., Polonsky, Tamar S., Rothman, Russell L., Harrington, Robert A., Hernandez, Adrian F. and Jones, W. Schuyler (2023). Internet versus noninternet participation in a decentralized clinical trial: lessons from the ADAPTABLE study. Journal of the American Heart Association, 12 (13) e027899, 1-18. doi: 10.1161/jaha.122.027899 |
|
2023 Journal Article Pragmatic evaluation of events and benefits of lipid lowering in older adults (PREVENTABLE): trial design and rationaleJoseph, Jacob, Pajewski, Nicholas M., Dolor, Rowena J., Sellers, Mary Ann, Perdue, Letitia H., Peeples, Sheronda R., Henrie, Adam M., Woolard, Nancy, Jones, W. Schuyler, Benziger, Catherine P., Orkaby, Ariela R., Mixon, Amanda S., VanWormer, Jeffrey J., Shapiro, Michael D., Kistler, Christine E., Polonsky, Tamar S., Chatterjee, Ranee, Chamberlain, Alanna M., Forman, Daniel E., Knowlton, Kirk U., Gill, Thomas M., Newby, L. Kristin, Hammill, Bradley G., Cicek, Mine S., Williams, Neely A., Decker, Jake E., Ou, Jiafu, Rubinstein, Jack, Choudhary, Gaurav ... Ramalingam, Ramesh (2023). Pragmatic evaluation of events and benefits of lipid lowering in older adults (PREVENTABLE): trial design and rationale. Journal of the American Geriatrics Society, 71 (6), 1701-1713. doi: 10.1111/jgs.18312 |
|
2022 Journal Article Racial disparities and excess cardiovascular mortality before and during the COVID-19 pandemic: time for a solutionObi, Koyenum and Effron, Mark B. (2022). Racial disparities and excess cardiovascular mortality before and during the COVID-19 pandemic: time for a solution. Mayo Clinic Proceedings, 97 (12), 2180-2183. doi: 10.1016/j.mayocp.2022.10.015 |
|
2022 Journal Article Importance of More Potent Antiplatelet Therapy in Myocardial Infarction With Cardiac Arrest or Cardiogenic ShockEffron, Mark B. (2022). Importance of More Potent Antiplatelet Therapy in Myocardial Infarction With Cardiac Arrest or Cardiogenic Shock. Mayo Clinic Proceedings, 97 (6), 1041-1043. doi: 10.1016/j.mayocp.2022.04.012 |
|
2022 Journal Article Proposal for a simple algorithmic approach to manage drug-drug interactions of oral anticoagulants with nirmatrelvir/ritonavir in COVID-19 outpatientsRizk, John G., Lazo, Jose G., Gupta, Aashish, Lavie, Carl J. and Effron, Mark B. (2022). Proposal for a simple algorithmic approach to manage drug-drug interactions of oral anticoagulants with nirmatrelvir/ritonavir in COVID-19 outpatients. Seminars in Thrombosis and Hemostasis, 49 (01), 085-088. doi: 10.1055/s-0042-1750024 |
|
2022 Journal Article To Anticoagulate or Not to Anticoagulate in COVID-19: Lessons after 2 YearsRizk, John G., Gupta, Aashish, Lazo, Jose G., Sardar, Partha, Henry, Brandon Michael, Lavie, Carl J. and Effron, Mark B. (2022). To Anticoagulate or Not to Anticoagulate in COVID-19: Lessons after 2 Years. Seminars in Thrombosis and Hemostasis, 49 (01), 062-072. doi: 10.1055/s-0042-1744302 |
